LT3275896T - Antikūnų gavimo procesas - Google Patents

Antikūnų gavimo procesas

Info

Publication number
LT3275896T
LT3275896T LTEP17173501.2T LT17173501T LT3275896T LT 3275896 T LT3275896 T LT 3275896T LT 17173501 T LT17173501 T LT 17173501T LT 3275896 T LT3275896 T LT 3275896T
Authority
LT
Lithuania
Prior art keywords
obtaining antibodies
antibodies
obtaining
Prior art date
Application number
LTEP17173501.2T
Other languages
English (en)
Inventor
Jean-Pascal Pierre Bilgischer
Philip Jonathan Bassett
Mark Robert Pearce-Higgins
Andrew John Kenny
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of LT3275896T publication Critical patent/LT3275896T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEP17173501.2T 2010-02-03 2011-02-02 Antikūnų gavimo procesas LT3275896T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1001791.1A GB201001791D0 (en) 2010-02-03 2010-02-03 Process for obtaining antibodies

Publications (1)

Publication Number Publication Date
LT3275896T true LT3275896T (lt) 2021-10-11

Family

ID=42082439

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP11702974.4T LT2531526T (lt) 2010-02-03 2011-02-02 Antikūnų gavimo būdas
LTEP17173501.2T LT3275896T (lt) 2010-02-03 2011-02-02 Antikūnų gavimo procesas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP11702974.4T LT2531526T (lt) 2010-02-03 2011-02-02 Antikūnų gavimo būdas

Country Status (20)

Country Link
US (3) US10487136B2 (lt)
EP (2) EP2531526B1 (lt)
JP (2) JP5820823B2 (lt)
KR (1) KR101779234B1 (lt)
CN (1) CN102812042B (lt)
AU (1) AU2011212493B2 (lt)
BR (1) BR112012019404B8 (lt)
CA (1) CA2788967C (lt)
DK (2) DK2531526T3 (lt)
ES (2) ES2647387T3 (lt)
GB (1) GB201001791D0 (lt)
HU (2) HUE055717T2 (lt)
IL (2) IL221266A (lt)
LT (2) LT2531526T (lt)
NO (1) NO2531526T3 (lt)
PL (2) PL2531526T3 (lt)
PT (2) PT3275896T (lt)
SG (2) SG10201408639RA (lt)
SI (2) SI3275896T1 (lt)
WO (1) WO2011095506A1 (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN02401A (lt) 2009-09-24 2015-08-21 Ucb Pharma Sa
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
PL2731973T3 (pl) 2011-07-13 2018-04-30 Ucb Biopharma Sprl Bakteryjny szczep gospodarz wykazujący ekspresję dsbc
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
WO2014041116A1 (en) 2012-09-17 2014-03-20 F. Hoffmann-La Roche Ag Method for the production of polypeptides in the periplasm of prokaryotic cells
CN104004095B (zh) * 2014-06-04 2016-11-23 博生吉医药科技(苏州)有限公司 一种cd7纳米抗体、其编码序列及应用
SG11201704836XA (en) 2014-12-22 2017-07-28 Ucb Biopharma Sprl Protein manufacture
IL252712B2 (en) 2014-12-22 2024-04-01 UCB Biopharma SRL Method of protein manufacture
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
JP7350313B2 (ja) 2016-12-16 2023-09-26 ブルーフィン バイオメディシン, インコーポレイテッド 抗cubドメイン含有タンパク質1(cdcp1)抗体、抗体薬物コンジュゲート、およびその使用方法
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN108251523A (zh) * 2016-12-27 2018-07-06 山东省医学科学院基础医学研究所 一种非小细胞肺癌分子标志物及其应用
WO2018216978A1 (en) * 2017-05-22 2018-11-29 Cj Healthcare Corporation Cell culture method at low temperature applicable to mass production of protein

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9215540D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US5655866A (en) 1995-03-20 1997-08-12 Bellanca; Joseph V. Method of folding a signature for use in bookbinding
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US7041479B2 (en) 2000-09-06 2006-05-09 The Board Of Trustess Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
CN101395269A (zh) * 2002-10-10 2009-03-25 戴弗萨公司 蛋白酶、编码这些蛋白酶的核酸及它们的制备和应用方法
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
GB0425534D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
US8470552B2 (en) * 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) * 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
SG11201704836XA (en) * 2014-12-22 2017-07-28 Ucb Biopharma Sprl Protein manufacture

Also Published As

Publication number Publication date
PL2531526T3 (pl) 2018-02-28
ES2647387T3 (es) 2017-12-21
EP2531526A1 (en) 2012-12-12
HUE055717T2 (hu) 2021-12-28
IL249501A0 (en) 2017-02-28
DK3275896T3 (da) 2021-09-20
HUE037191T2 (hu) 2018-08-28
IL249501B (en) 2020-08-31
EP3275896A1 (en) 2018-01-31
CN102812042B (zh) 2014-12-24
LT2531526T (lt) 2017-12-11
SG183151A1 (en) 2012-09-27
BR112012019404B1 (pt) 2022-03-22
CA2788967A1 (en) 2011-08-11
EP2531526B1 (en) 2017-08-16
BR112012019404A2 (pt) 2018-03-20
US12275777B2 (en) 2025-04-15
KR20130016205A (ko) 2013-02-14
PT2531526T (pt) 2017-11-16
NO2531526T3 (lt) 2018-01-13
US10487136B2 (en) 2019-11-26
DK2531526T3 (da) 2017-11-13
IL221266A (en) 2016-12-29
EP3275896B1 (en) 2021-06-16
PT3275896T (pt) 2021-09-20
CA2788967C (en) 2019-02-26
CN102812042A (zh) 2012-12-05
ES2886109T3 (es) 2021-12-16
US20220348641A1 (en) 2022-11-03
JP5820823B2 (ja) 2015-11-24
PL3275896T3 (pl) 2021-12-13
US20130060009A1 (en) 2013-03-07
BR112012019404B8 (pt) 2022-05-10
KR101779234B1 (ko) 2017-09-18
SG10201408639RA (en) 2015-02-27
JP2016005483A (ja) 2016-01-14
JP6141937B2 (ja) 2017-06-07
US20200071387A1 (en) 2020-03-05
JP2013518572A (ja) 2013-05-23
HK1179272A1 (en) 2013-09-27
US11384136B2 (en) 2022-07-12
SI3275896T1 (sl) 2021-11-30
WO2011095506A1 (en) 2011-08-11
SI2531526T1 (sl) 2017-12-29
IL221266A0 (en) 2012-10-31
AU2011212493A1 (en) 2012-08-30
GB201001791D0 (en) 2010-03-24
AU2011212493B2 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
CY2019040I2 (el) Aνti-il-23 αντισωματα
LT3275896T (lt) Antikūnų gavimo procesas
CY2017025I2 (el) Αντιδοτα αντιπηκτικων
HRP20181189T1 (hr) Poboljšani sklop bispecifičnih protutijela
DK3284754T3 (da) Anti-cd38-antistoffer
DK2521736T3 (da) Humaniserede antistoffer
DK3323830T3 (da) Anti-gd2 antibodies
HUE037140T2 (hu) Humán GDF8-hoz kötõdõ ellenanyagok
EP2576492A4 (en) TREPROSTINILHERSTELLUNG
HRP20181320T1 (hr) Ljudska anti-tau protutijela
HUE056588T2 (hu) Eljárás poliolefinek elõállítására
CR20130228A (es) Anticuerpos neutralizadores anti-ccl20
PL3299356T3 (pl) Sposób wytwarzania pleuromutylin
CO6791565A2 (es) Anticuerpos anti-notch1
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
BR112014003878A2 (pt) síntese de r-bifenilalaninol
PT2736340T (pt) Biocontrolo de nemátodos
LT2632586T (lt) Katalizatoriaus gamybos būdas
IL225346A0 (en) Serum preparation
PL2688948T3 (pl) Sposób otrzymywania roztworu przyspieszacza
EP2691361A4 (en) SYNTHESIS OF DIAZIDEN
HUE043576T2 (hu) Antitestek notum pektinacetilészterázhoz
HRP20190030T1 (hr) Postupak pročišćavanja protutijela
CO6841994A2 (es) Anticuerpos